Price (delayed)
$3.59
Market cap
$967.77M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.12
Enterprise value
$1.27B
MannKind Corporation focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, its
There are no recent dividends present for MNKD.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.